Evidence-based natural medicine backed by peer-reviewed research
Findings supported by replicated human studies, systematic reviews, clinical guidelines, or regulatory approval for a specific indication.
Human trials and observational studies can identify benefit or association, but study design, size, endpoints, and replication determine confidence.
Phase I/II studies primarily assess safety, dosing, and preliminary activity. They do not establish that a treatment improves survival.
Cell and animal studies can reveal mechanisms and justify trials, but many promising laboratory findings do not translate into effective human treatments.
A biologically plausible idea, testimonial, or historical account is not proof. It should be clearly identified and tested prospectively.
Evidence is indication-specific. A medicine proven for parasites is not thereby proven for cancer, and veterinary products must never be used in people.
NOA Health evidence policy: Priority is given to official Nobel records, WHO/IARC and government health agencies, systematic reviews, randomised controlled trials, registered clinical trials, and indexed peer-reviewed research. Cell studies, animal studies, case reports, and testimonials are labelled separately and never presented as proof of patient benefit.
Last editorial review: July 2026. Research changes over time; readers should open the linked source and check for corrections, retractions, updated reviews, and completed trial results.
Peer-reviewed research supporting natural medicine approaches
Carcinogenesis. 2014 Mar;35(3):515-27
link: DOI: 10.1093/carcin/bgt480
This influential review argues that altered energy metabolism and mitochondrial dysfunction are important in cancer biology. Cancer is heterogeneous, and mainstream evidence supports interacting genetic, epigenetic, metabolic, immune, and environmental mechanisms.
PLoS One. 2007 May 2;2(5):e536
link: DOI: 10.1371/journal.pone.0000536
The ketogenic diet significantly delayed tumor growth and increased survival time in mice with systemic metastatic cancer.
Front Nutr. 2018 Jan 5;4:20
link: DOI: 10.3389/fnut.2017.00020
This small human report contributes feasibility information, not proof of efficacy. Larger controlled trials are required to determine whether ketogenic interventions improve cancer outcomes.
Lancet Oncol. 2009;10(4):321-322
link: DOI: 10.1016/S1470-2045(09)70096-8
WHO classification of infectious agents as carcinogenic to humans, including liver flukes and other parasites.
Nature. 2002;420(6917):860-867
link: DOI: 10.1038/nature01322
Review showing how chronic inflammatory conditions, including parasitic infections, create environments conducive to cancer development.
PLoS Negl Trop Dis. 2015;9(9):e0004152
link: DOI: 10.1371/journal.pntd.0004152
This unusual case documented malignant transformation of tapeworm cells in an immunocompromised patient. It should not be generalized to mean that common intestinal parasites are a general cause of human cancer.
J Investig Med. 2011;59(6):881-886
link: DOI: 10.2310/JIM.0b013e31821b8755
Review of vitamin D signalling in innate and adaptive immunity. Associations between low vitamin D status and disease do not by themselves prove that supplementation prevents or treats those diseases.
Am J Public Health. 2006;96(2):252-261
link: DOI: 10.2105/AJPH.2004.045260
Review reporting observational associations between vitamin D status, geography, and several cancers. Observational associations can be confounded and are not equivalent to evidence from randomised supplementation trials.
JAMA. 2020;324(11):1099-1100
link: DOI: 10.1001/jama.2020.15946
Retrospective observational study reporting an association between likely vitamin D deficiency and positive COVID-19 tests. It did not establish that supplementation prevents infection or improves outcomes.
Science. 2018;359(6371):97-103
link: DOI: 10.1126/science.aan4236
Gut microbiome composition significantly influences response to cancer immunotherapy. Patients with favorable microbiomes had better treatment outcomes.
Proc Natl Acad Sci USA. 2007;104(34):13780-13785
link: DOI: 10.1073/pnas.0706625104
Demonstration of significant microbiome imbalances in IBD patients, supporting dysbiosis as a key factor in chronic inflammatory diseases.
Proc Natl Acad Sci USA. 2005;102(38):13604-13609
link: DOI: 10.1073/pnas.0506390102
Preclinical work found that pharmacologic ascorbate generated hydrogen peroxide and was selectively toxic to some cancer-cell models. This laboratory result does not establish clinical efficacy in patients.
Br J Cancer. 2002;86(11):1737-1743
link: DOI: 10.1038/sj.bjc.6600374
Secondary analyses suggested possible effects in some groups, but later large trials did not establish selenium supplements as a general cancer-prevention treatment. Supplementation can also cause harm at excessive doses.
What the research establishes, what remains experimental, and where further trials are needed
What the prize recognised: Warburg received the prize for discovering the nature and mode of action of the respiratory enzyme—not for proving that sugar causes cancer or that diet cures cancer.
The Nobel Prize in Physiology or Medicine 1931
Vander Heiden et al., Understanding the Warburg effect, Science (2009)
Current interpretation: Aerobic glycolysis is a hallmark of many cancers, but tumour cells are metabolically diverse and many retain mitochondrial respiration. Metabolic targeting is an active research field, not a universal dietary cure.
What the prize recognised: Discovery of Helicobacter pylori and its role in gastritis and peptic ulcer disease. H. pylori is also classified as a Group 1 carcinogen because chronic infection increases gastric-cancer risk.
The Nobel Prize in Physiology or Medicine 2005
US National Cancer Institute: H. pylori and cancer
Correct scope: This establishes that a specific bacterium causes specific diseases and increases risk of specific cancers. It does not show that parasites are the cause of all cancers.
What the prize recognised: Discoveries leading to avermectin and ivermectin, transformative treatments for infections caused by roundworm parasites, including river blindness and lymphatic filariasis.
The Nobel Prize in Physiology or Medicine 2015
Official Nobel Prize press release
Correct scope: The Nobel recognition establishes ivermectin's impact against susceptible parasites. It does not establish ivermectin as a cancer treatment; that is a separate question requiring cancer trials.
What the prize recognised: Discovery of human papillomaviruses causing cervical cancer. Persistent infection with high-risk HPV types is also causally linked to several anogenital and oropharyngeal cancers.
The Nobel Prize in Physiology or Medicine 2008
US National Cancer Institute: HPV and cancer
Clinical impact: This discovery enabled evidence-based screening and vaccination strategies that prevent HPV infection and reduce cervical precancer and cancer risk.
What the prize recognised: Cancer therapy through inhibition of negative immune regulation. Their work on CTLA-4 and PD-1 led to immune-checkpoint medicines with demonstrated benefit in multiple cancers.
The Nobel Prize in Physiology or Medicine 2018
US National Cancer Institute: checkpoint inhibitors
Why it matters here: It demonstrates the standard required to move from mechanism to proven treatment: reproducible biology followed by controlled human trials showing meaningful outcomes.
Evidence: Chronic infection with Clonorchis sinensis or Opisthorchis viverrini increases the risk of cholangiocarcinoma. IARC classifies these particular liver flukes as carcinogenic to humans.
Lancet Oncol. 2009 Apr;10(4):321-2
PubMed: IARC carcinogen classification
Correct scope: The evidence is species- and organ-specific. It does not validate claims that Fasciolopsis buski causes all cancers.
Evidence: Long-term Schistosoma haematobium infection is an established cause of squamous-cell carcinoma of the bladder in endemic regions.
Acta Trop. 2009 Nov;112(2):99-104
PubMed: Schistosomiasis and bladder cancer
Clinical meaning: Prevention, diagnosis, and evidence-based antiparasitic treatment matter in exposed populations; this is not evidence for routine parasite cleanses in uninfected people.
Context: IARC estimates that a defined subset of cancers worldwide is attributable to infectious agents such as H. pylori, HPV, hepatitis viruses, Epstein–Barr virus, and specific parasites.
IARC: global burden of cancer attributable to infections
Conclusion: Infection prevention and treatment can prevent some cancers. Evidence does not support a single-pathogen explanation for cancer as a whole.
What has been observed: Laboratory studies report effects on cancer-cell signalling, apoptosis, stem-like cells, and drug resistance across several models. Concentrations effective in vitro may not be safely achievable in humans.
Am J Cancer Res. 2018;8(2):317-331
PubMed: The multitargeted drug ivermectin
ClinicalTrials.gov: current cancer studies involving ivermectin
Evidence limit: Mechanistic and preclinical promise is not proof of clinical benefit. Ivermectin is not an approved cancer therapy and should not replace standard treatment.
Why it is studied: This human antiparasitic benzimidazole disrupts microtubules and has shown anticancer activity in cell and animal models. Small early-phase studies have explored dosing and safety in oncology.
ecancermedicalscience. 2014;8:443
PubMed: Repurposing Drugs in Oncology—mebendazole
Scientific Reports: phase 2a monotherapy study in advanced gastrointestinal cancer
ClinicalTrials.gov: current cancer studies involving mebendazole
Evidence limit: In the small phase 2a study, individualised dosing was feasible but all evaluable patients had progressive disease; highly variable drug exposure was a major challenge. Human data have not established improved survival. Oncology use remains investigational and can involve liver, blood-count, and drug-interaction risks.
What has been observed: Fenbendazole, a veterinary benzimidazole, altered microtubules and several cellular pathways in laboratory cancer models. This is a research signal, not evidence that it cures cancer in people.
Scientific Reports. 2018;8:11926
PubMed: Fenbendazole and cancer-cell pathways
Safety status: Fenbendazole is formulated and authorised for animals, not humans. Testimonials such as the “Joe Tippens protocol” are not controlled clinical evidence. Veterinary formulations may present additional purity and dosing risks.
Why this matters: They are related benzimidazoles, but different molecules with different human-use status, pharmacokinetics, formulations, and evidence. Results cannot be transferred from one drug to another.
NIH PubChem: fenbendazole compound record
NIH PubChem: mebendazole compound record
Research standard: A credible repurposing case requires achievable exposure, pharmacology, toxicology, and controlled human outcomes—not just a shared drug class or mechanism.
Finding: Systematic reviews show that industry-sponsored drug and device studies more often report sponsor-favourable results and conclusions. This supports transparency, preregistration, data access, and independent replication.
Cochrane Database Syst Rev. 2017
PubMed: Industry sponsorship and research outcome
What it does not prove: Bias in some research is not evidence that a particular unproven treatment works or that negative results are necessarily suppression.
Finding: Small samples, flexible analyses, selective reporting, and low prior probability can produce false-positive findings. Better methods strengthen both conventional and repurposed-drug research.
PLoS Med. 2005;2(8):e124
PubMed: Why most published research findings are false
Responsible conclusion: Ask whether a claim has independent replication, clinically meaningful endpoints, an appropriate control group, and a plausible human dose.
Risk: Repurposed medicines can cause toxicity, interact with chemotherapy and supportive medicines, alter liver enzymes, or delay treatment known to improve survival.
US National Cancer Institute: complementary and alternative medicine
US FDA: risks of using non-prescribed or animal ivermectin products
Best next step: Discuss trial eligibility and any proposed off-label medicine with an oncologist and pharmacist who can assess evidence, dose, interactions, monitoring, and legal availability.
Finding: In 25,871 US adults, vitamin D3 at 2,000 IU/day did not produce a statistically significant reduction in the primary endpoint of invasive cancer incidence during the trial's median follow-up.
N Engl J Med. 2019;380:33-44
PubMed: VITAL cancer and cardiovascular trial
Interpretation: Vitamin D remains essential for health and deficiency should be managed appropriately, but this large trial does not support presenting routine high-dose supplementation as a general cancer-prevention treatment.
Finding: Selenium, vitamin E, or their combination did not significantly prevent prostate cancer in the large SELECT randomised trial. Later follow-up identified an increased prostate-cancer risk in the vitamin E group.
JAMA. 2009;301(1):39-51
PubMed: updated SELECT vitamin E follow-up
Interpretation: Plausible antioxidant mechanisms and earlier secondary findings were not enough. Large controlled trials are essential, and more supplementation is not necessarily safer or better.
Finding: Among first-degree relatives of patients with gastric cancer who were infected with H. pylori, eradication treatment reduced the incidence of gastric cancer compared with placebo during long-term follow-up.
N Engl J Med. 2020;382:427-436
PubMed: H. pylori treatment and gastric cancer prevention
Interpretation: This is strong evidence for targeted diagnosis and eradication of a proven carcinogenic infection in an appropriate population—not for nonspecific antimicrobial or parasite treatment.
Finding: A population-based observational study found major reductions in cervical cancer and grade 3 cervical intraepithelial neoplasia among cohorts offered HPV vaccination at younger ages.
Lancet. 2021;398:2084-2092
PubMed: effect of the English HPV vaccination programme
Interpretation: It provides real-world confirmation that preventing a proven cancer-causing infection can prevent cancer.
Finding: Modern cancer biology integrates genomic instability, altered metabolism, immune evasion, inflammation, cell-state plasticity, the microbiome, and interactions with the tumour microenvironment.
Cancer Discov. 2022;12(1):31-46
PubMed: Hallmarks of Cancer—New Dimensions
Interpretation: Metabolism and infection are important parts of cancer science, but evidence does not support reducing every cancer to one parasite, one nutrient, one toxin, or one fuel source.
Additional reading across nutrition, supplementation, and research integrity.
Crit Rev Clin Lab Sci. 2014;51(5):259-275
link: DOI: 10.3109/10408363.2014.907563
Comprehensive review of NAC's role in boosting glutathione levels, reducing oxidative stress, and supporting detoxification pathways.
Am J Clin Nutr. 2007;85(3):837S-844S
link: DOI: 10.1093/ajcn/85.3.837S
Review showing zinc deficiency severely compromises immune function, while adequate zinc supports T-cell function and natural killer cell activity.
Diabetologia. 2007;50(9):1795-1807
link: DOI: 10.1007/s00125-007-0716-y
Randomized trial showing Paleolithic diet superior to diabetes diet for improving glucose tolerance and cardiovascular risk factors.
Popul Dev Rev. 2007;33(2):321-365
link: DOI: 10.1111/j.1728-4457.2007.00171.x
Analysis of hunter-gatherer populations showing low rates of cardiovascular disease, diabetes, and cancer compared to modern populations.
JAMA. 2017;318(23):2306-2316
PubMed: randomised clinical trial
A specific, regulated medical device delivering tumour-treating fields improved outcomes when added to maintenance temozolomide in this indication. This evidence is device-, protocol-, and disease-specific.
A positive trial for one calibrated medical device cannot validate unrelated devices or claims that untested frequencies selectively destroy pathogens or cancer. Those claims require their own reproducible laboratory evidence and controlled clinical trials.
PLoS Med. 2017;14(3):e1002263
PubMed: Industry sponsorship and research outcome
Systematic review showing industry sponsorship of drug studies is associated with more favorable efficacy results and conclusions than sponsorship by other sources.
Account Res. 2009;16(6):301-319
link: DOI: 10.1080/08989620903362519
Investigation revealing widespread pharmaceutical industry ghostwriting of medical publications to promote their products while hiding conflicts of interest.
N Engl J Med. 2008;358(3):252-260
link: DOI: 10.1056/NEJMsa065779
Analysis showing selective publication of positive antidepressant trials while negative studies were suppressed, creating false impression of drug efficacy.
Use these primary databases to check publications, trial status, systematic reviews, and evidence-based cancer information.
Public registry of interventional and observational clinical studies.
Search registered trialsIndependent systematic reviews of healthcare interventions.
Browse Cochrane reviewsEvidence summaries on cancer biology, prevention, treatment, and clinical trials.
Visit the NCIMethods that support safe, measurable, and clinically interpretable decision-making
Validated tests selected for a specific clinical question and interpreted against appropriate reference standards.
Established imaging, histopathology, and molecular testing used by qualified clinical teams.
Clinically appropriate glucose, lipid, liver, kidney, and nutritional markers monitored over time.
Pharmacist-led review of prescriptions, supplements, interactions, contraindications, and monitoring needs.